# Inmune Bio Inc. (INMB)

**Exchange:** NASDAQ  
**Sector:** Healthcare  
**Market cap:** $30M  
**Price:** $1.21 (-0.82%)

> Inmune Bio Inc. is a biotechnology company focused on the development of innovative therapies for modulating the immune system. The primary purpose of its research and development efforts is to create treatments that help in managing and potentially curing a range of conditions by targeting innate immune functions. This approach is significant in the medical field, particularly in autoimmune diseases, cancer, and neurodegenerative disorders, where the immune system's regulation can have profound impacts on disease progression and patient outcomes. By harnessing the body's own defense mechanisms, Inmune Bio Inc. aims to advance therapeutic solutions that are both effective and minimize adverse side effects. Operating in a rapidly evolving sector, the company holds an influential role in the biotechnology market, contributing to cutting-edge scientific advancements. By fostering collaborations with research institutions and leveraging its proprietary technologies, Inmune Bio Inc. continues to push the boundaries of immune-based treatments, offering hope for novel applications across different medical conditions.

## Income Statement (Annual, USD)

| Fiscal Year | Revenue | Gross Profit | Operating Income | Net Income | EPS (dil.) |
| --- | --- | --- | --- | --- | --- |
| 2025 | $50,000 | — | -$47M | -$46M | $-1.86 |
| 2024 | $14,000 | — | -$43M | -$42M | $-2.11 |
| 2023 | $155,000 | — | -$30M | -$30M | $-1.67 |
| 2022 | $374,000 | — | -$26M | -$27M | $-1.52 |
| 2021 | $181,000 | — | -$29M | -$30M | $-1.88 |
| 2020 | $11,000 | — | -$12M | -$12M | — |
| 2018 | — | — | -$12M | -$12M | — |
| 2017 | — | — | -$981,480 | -$831,486 | — |

## Balance Sheet (Annual, USD)

| Fiscal Year | Total Assets | Total Liabilities | Equity | Cash | Long-term Debt |
| --- | --- | --- | --- | --- | --- |
| 2025 | $32M | $9M | $24M | $25M | — |
| 2024 | $40M | $7M | $32M | $21M | $15M |
| 2023 | $57M | $19M | $37M | $36M | — |
| 2022 | $82M | $22M | $60M | $52M | $15M |
| 2021 | $100M | $20M | $80M | $75M | $15M |
| 2020 | $41M | $2M | $39M | $22M | — |
| 2018 | $17M | $823,766 | $17M | $186,204 | — |
| 2017 | $18M | $309,717 | $18M | $1M | — |

## Cash Flow (Annual, USD)

| Fiscal Year | Operating Cash Flow | CapEx | Free Cash Flow |
| --- | --- | --- | --- |
| 2025 | -$23M | $1M | -$24M |
| 2024 | -$33M | — | — |
| 2023 | -$12M | — | — |
| 2022 | -$23M | — | — |
| 2021 | -$29M | — | — |
| 2020 | -$9M | — | — |
| 2019 | -$5M | — | — |
| 2018 | -$2M | — | — |
| 2017 | -$761,834 | — | — |

Source: [CompaniesByCap](https://companiesbycap.com/company/INMB)